Brief: Nasdaq Grants Vaccinex Extension Until March 4, 2024 To Regain Compliance With Listing Rule
04/12/2023 14:01
Dec 4 (Reuters) - Vaccinex Inc VCNX.O :
* NASDAQ GRANTS VACCINEX EXTENSION UNTIL MARCH 4, 2024 TO
REGAIN
COMPLIANCE WITH LISTING RULE
Source text for Eikon: ID:nGNX1SfpRs
Further company coverage: VCNX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease